

- mining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection. *Journal of Gastroenterology* 45 : 656-665 (2010)
- 8) Sakamoto N, Nakagawa M, Tanaka Y *et al* : Association of IL28B Variants With Response to Pegylated-Interferon Alpha Plus Ribavirin Combination Therapy Reveals Intersubgenotypic Differences Between Genotypes 2a and 2b. *Journal of Medical Virology* 83 : 871-878 (2011)
 - 9) Akuta N, Suzuki F, Sezaki H *et al* : Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. *Intervirology* 48 : 372-380 (2005)
 - 10) Akuta N, Suzuki F, Sezaki H *et al* : Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. *Journal of Medical Virology* 78 : 83-90 (2006)
 - 11) Akuta N, Suzuki F, Hirakawa M *et al* : Amino Acid Substitution in Hepatitis C Virus Core Region and Genetic Variation Near the Interleukin 28B Gene Predict Viral Response to Telaprevir with Peginterferon and Ribavirin. *Hepatology* 52 : 421-429 (2010)
 - 12) Fellay J, Thompson AJ, Ge DL *et al* : ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. *Nature* 464 : 405-408 (2010)
 - 13) Sakamoto N, Tanaka Y, Nakagawa M *et al* : ITPA gene variant protects against anemia induced by pegylated interferon-alpha and ribavirin therapy for Japanese patients with chronic hepatitis C. *Hepatology Research* 40 : 1063-1071 (2010)
 - 14) Tanaka Y, Kurosaki M, Nishida N *et al* : Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. *Human Molecular Genetics* 20 : 3507-3516 (2011)
 - 15) Nakagawa M, Sakamoto N, Watanabe M *et al* : Association of ITPA gene variation and serum ribavirin concentration with a decline in blood cell concentrations during pegylated interferon-alpha plus ribavirin therapy for chronic hepatitis C. *Hepatol Int* (2012) [Epub]

特

集

Gastrointestinal
Research

ゲノムワイド関連解析からみえてきた消化器疾患

HCV 治療抵抗性関連遺伝子の 同定と治療展開

中川美奈* 坂本直哉**

Summary

インターロイキン (IL) 28B の遺伝子多型は、2009 年にはじめて C 型肝炎の治療効果に関連する遺伝子として報告された。IL28B 遺伝子座の代表的な一塩基置換 (SNP) である rs8099917 の minor allele (TG/GG) をもつ患者群は、もたない (TT) 患者群にくらべ強い有意差をもってペグインターフェロン・リバビリン (PEG-IFN・RBV) 療法が無効であることが報告されたが、テラプレビル (TPV) を加えた 3 剤併用療法においても治療抵抗性の予測因子として重要であることが報告されている。C 型慢性肝炎の治療にあたっては、IL28B を含めた詳細な宿主およびウイルス因子解析による治療前効果予測により、根治の見込める患者を高い中率で選別し、治療導入を強く勧め、また治療抵抗性と判定された患者は STAT-C 併用療法、あるいは PEG-IFN- λ 療法に振り替えるなど、治療のオーダーメイド化の展開が期待される。

Key words

C 型慢性肝炎 ゲノムワイド関連解析 (GWAS) インターロイキン (IL) 28B 治療抵抗性 インターフェロン (IFN)- λ

はじめに

慢性活動性肝炎患者の肝病態進展の阻止にウイルス排除は不可欠であるが、わが国における C 型慢性肝炎の抗ウイルス療法は、1992 年に認可されたインターフェロン (IFN) がその中心的役割を果たしてきた。持続型 IFN 製剤であるペグインターフェロン (PEG-IFN) は、その簡便性および有効性、さらにリバビリン (RBV) との併用による再燃抑制効果が認められ、PEG-IFN・RBV 併用療法が日本および世界の標準治療となったが、

難治例であるゲノタイプ 1 型高ウイルス量症例の sustained virological response (SVR) 率は 50% 前後であり^{1,2)}、長期にわたる治療期間や副作用の問題、また副作用などによる薬剤の中止減量が治療効果低下につながるものが課題となっていた。また IFN に対する反応性には人種間の差があり、遺伝的な治療感受性決定因子の存在も以前から示唆されていた³⁾。一方、2000 年にヒトゲノムの配列が決定されて以来、近年の遺伝子情報処理技術の飛躍的な進歩による網羅的なゲノムワイド関連解析 (genome-wide association study : GWAS)

* NAKAGAWA Mina/東京医科歯科大学消化器内科

** SAKAMOTO Naoya/北海道大学大学院医学研究科内科学講座消化器内科学分野

特集

ゲノムワイド関連解析からみえてきた消化器疾患

がおこなわれるようになり、さまざまな疾患発症の原因遺伝子の報告が盛んになされるようになった。このような状況で、2009年にはじめてC型肝炎の自然経過・治療効果に関連する遺伝子として、インターロイキン(IL)28Bの遺伝子多型が報告された。

1 C型肝炎の自然経過・治療効果とGWAS

Tanaka およびわれわれは、PEG-IFN・RBV療法の有効性に関連するヒト遺伝子多型を同定するため、GWASを実施した。すなわち、同療法が有効であった患者と無効(null-response)であった患者に対して、ヒト遺伝子の約90万カ所の一塩基置換(single nucleotide polymorphism: SNP)をDNAマイクロアレイ(Affymetrix® Genome-Wide Human SNP Array)を用いて検出し、個々のSNPの表現型と治療効果の関連性を検討した。その結果、19番染色体上のIL28B遺伝子周辺に、治療無効に強く関連する一連の有意なSNPを同定した⁴⁾。すなわち、IL28B遺伝子座の代表的なSNPであるrs8099917(TT/TG/GG)のminor allele(TG/GG)をもつ患者群は、もたない(TT)患者群にくらべ強い有意差をもってPEG-IFN・RBV療法が無効であった($p=2.68 \times 10^{-32}$)。さらに年齢、性別、肝線維化、治療歴、ウイルス量、alanine aminotransferase(ALT)、血小板データとともに多変量解析をおこなった結果、IL28B SNPが治療無効を最も強く予測する独立した因子として同定された($p<0.001$)。

このIL28Bの関連を示す同様の報告は、独立した3つの研究グループからほぼ同時に報告され、人種を超えた遺伝要因であることが証明された⁵⁾⁶⁾。さらにGeら⁶⁾は、白人、黒人、ヒスパニックの患者群で検討した結果、IFN治療感受性に関連するIL28Bのmajor alleleの頻度はアジアで80~90%と最も多く、つづいて白人およびヒスパニックが70~80%、そして黒人は30~50%と低

表 1. IL28B SNP (rs12979860) と急性 C 型肝炎のウイルス消失率 (n=1,008)

ゲノタイプ	血中ウイルス消失率	p 値 (対 C/C)
T/T	23.4%	4×10^{-7}
C/T	29.5%	4×10^{-11}
C/C	53%	—

(Thomas DL *et al.* 2009⁷⁾より改変引用)

値であり、この頻度がPEG-IFN・RBV療法の著効率と正に相関していることが示されている。また、Thomasら⁷⁾はIL28B SNPがC型肝炎の自然治癒率に関連することを報告しており、IL28 major typeの症例は、minor alleleをもつ症例にくらべ自然治癒率が約3倍高率であった(表1)。

2 IL28B と IFN-λ ファミリー

IL28BはIFN-λ3とよばれ、IL28A(λ2)およびIL29(λ1)と類似の構造をもつファミリー蛋白である。IFN-λは、2003年にIFN関連蛋白の共通構造にもとづいた蛋白データベース検索により同定された新しいクラスのIFNであり、生体における詳細な機能はいまだ不明である⁸⁾⁹⁾。IFN-λの3つのアイソフォームは共通のクラスIIサイトカイン受容体(IL28R)とIL10Rβ複合体に結合したあと、IFN-α同様細胞内でsignal transducer and activator of transcription(STAT)1/2をリン酸化しIFN誘導遺伝子の発現を誘導する¹⁰⁾。つまり、IFN-λはIFN-α・βと受容体下流のシグナルを共有しているが、シグナル活性化誘導能はIFN-α、βにくらべて弱い。一方、PEG-IFN・RBV療法抵抗性であるIL28B minor alleleを有する患者では、リンパ球のIL28B発現が有意に低く、IL28B産生不十分な遺伝子型と考えられる⁴⁾。したがって、IFN-λを大量投与、または産生誘導する治療が、治療不応例に対する新たな方策となる可能性が十分ある。事実、現在PEG化されたIL29製剤の臨床試験が欧州で進行しており、IFN-α製剤にくらべ副作用が少なく有効性が期

表 2. ゲノタイピングに用いられる IL28B SNPs

NCBI reference ID	Allele		報告者
	major	minor	
rs12979860	C	T	Ge D <i>et al</i> ⁽⁶⁾
rs8099917	T	G	Tanaka Y <i>et al</i> ⁽⁴⁾ , Suppiah V <i>et al</i> ⁽⁵⁾

待されている。

3 ■ IL28B ゲノタイピング法

IL28B 遺伝子座には IFN 治療効果に強く関連する複数の SNP が存在するが、これらはすべてが強い連鎖不平衡を伴っておりハプロタイプを形成している。したがって、最も関連の強い特定の 1 つの SNP (タグ SNP) を調べれば、残りの SNP を推測することができる。このタグ SNP としては、現在のところ rs12979860⁽⁶⁾、または rs8099917⁽⁴⁾⁽⁵⁾ の 2カ所が *de facto* standard として使用され、それぞれ固有の核酸が major allele および minor allele を代表している (表 2)。SNP の検出法にはいくつかの方法があるが、少数の特定の SNP を検出するにはシーケンス法、Taqman[®] アッセイなどが一般的に用いられる。

ゲノタイピングを含む遺伝子検査では、生涯変化しない個人の重要な遺伝学的情報が扱われるため、検査実施時に、個人の遺伝学的情報の保護、検査に用いた生体試料の取り扱い、検査前後の遺伝カウンセリングなどを被検者に十分に説明し、インフォームド・コンセントを取ったうえでこなわなければならない。また厚生労働省・文部科学省・経済産業省の「ヒトゲノム・遺伝子解析研究に関する倫理指針」に則して、しかるべき施設で倫理委員会の承認を得たうえで施行しなければいけない。

4 ■ IL28B 多型と PEG-IFN・RBV 治療効果

2004 年 12 月より、本学および関連施設でおこ




図 1. 自験例：C 型慢性肝炎患者における IL28B SNP (rs8099917) の頻度 (n=431)

なった PEG-IFN・RBV 療法の最終効果判定可能であったゲノタイプ 1 の 213 例を対象に、IL28B SNP rs8099917 の解析をおこない、ウイルス、宿主因子とあわせ治療効果との関連を検討した。IL28B ゲノタイプの頻度は TT : 73.1%、TG : 25.8%、GG : 1.0% であり、minor allele (G) 頻度は 0.139 であった (図 1)。IL28B SNP は治療効果と強く関連しており、SVR は TT 群 52% にくらべ、TG+GG 群では 16% と有意に低率であり ($p = 4.1 \times 10^{-15}$)、その 67% が無効であった (図 2)。TG、GG 群では TT 群にくらべ治療早期抗ウイルス効果 [rapid virologic response (RVR), early virologic response (EVR)] はいずれも低率であっ




図 2. C 型慢性肝炎患者、ゲノタイプ 1b、高ウイルス量症例における IL28B SNP (rs8099917) と PEG-IFN/RBV48 週治療効果

た。IFN 感受性決定領域 (interferon sensitivity-determining region : ISDR) 変異 2 以上の症例では、IL28B 多型にかかわらず治療高感受性であったが (SVR TT : 71%, TG+GG : 75%), ISDR 変異 0,1 症例では IL28B 変異群で SVR は有意に低率であった (46% vs. 18%, $p < 0.001$)。また、IL28B 変異とコア 70/91 変異は連鎖しており、TG+GG 治療抵抗群でコア変異が有意に高頻度であった ($p < 0.01$)。以上の結果より、ゲノタイプ 1 かつ ISDR 変異 2 以上の症例では、IL28B 多型のいかににかかわらず良好な治療効果が得られることがわかり、ゲノタイプ 2 における IL28B と治療効果の関係でも認められたように¹¹⁾、治療高感受性のウイルスでは、IL28B が治療効果に与える影響は弱いことが確認された。

一方、ISDR 変異 1 以下、IL28B minor allele 症例では、高率に無効となる。現在のところ、無効例に対しては有効な再治療法がなく、今後登場する specifically targeted antiviral therapy for HCV (STAT-C) 薬を含んだ新規治療法の早期導入が待たれている。

このような状況のなか、STAT-C 薬第 1 号として認可されたテラプレビル (TPV) を加えた 3 剤併用療法においても、IL28B 変異は治療効果予測因子として重要であることが報告されている¹²⁾¹³⁾。宿主側抵抗因子である IL28B 変異とウイルス側抵抗因子であるコア変異を組み合わせることで、TPV 併用 3 剤併用療法の効果をより詳細に予測できることは、臨床上も非常に有意義なデータであるとともに、それぞれの治療抵抗性機序を解明することは、無効例に対する有効な治療法開発に向けての最重要事項の 1 つと考えられる。

おわりに

C 型慢性肝炎の治療にあたっては、IL28B を含めた詳細な宿主およびウイルス因子解析による治療前効果予測により、抗ウイルス療法導入症例を慎重に見きわめることが治療の質の向上に重要である。今後新規薬剤の登場とともに上述の宿主遺伝子情報を検討し、根治の見込める患者を高の中率で選別し、治療導入を強く勧め、また治療抵抗性と判定された患者は STAT-C 併用療法、あるいは PEG-IFN- λ 療法に振り替えるなど、治療のオーダーメイド化の展開が期待される。

【謝辞】

名古屋市立大学 田中靖人先生
 国立国際医療センター 溝上雅史先生
 お茶の水理科大学カンファレンス共同研究協力施設

文 献

- 1) Fried MW, Shiffman ML, Reddy KR *et al* : Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 347 : 975-982, 2002
- 2) Zeuzem S, Feinman SV, Rasenack J *et al* : Peginterferon alfa-2a in patients with chronic hepatitis C. *N Engl J Med* 343 : 1666-1672, 2000
- 3) Rosen HR, Gretch DR : Hepatitis C virus : current understanding and prospects for future therapies. *Mol Med Today* 5 : 393-399, 1999
- 4) Tanaka Y, Nishida N, Sugiyama M *et al* : Ge-

- nome-wide association of *IL28B* with response to pegylated interferon- α and ribavirin therapy for chronic hepatitis C. *Nat Genet* **41** : 1105-1109, 2009
- 5) Suppiah V, Moldovan M, Ahlenstiel G *et al* : *IL28B* is associated with response to chronic hepatitis C interferon- α and ribavirin therapy. *Nat Genet* **41** : 1100-1104, 2009
 - 6) Ge D, Fellay J, Thompson AJ *et al* : Genetic variation in *IL28B* predicts hepatitis C treatment-induced viral clearance. *Nature* **461** : 399-401, 2009
 - 7) Thomas DL, Thio CL, Martin MP *et al* : Genetic variation in *IL28B* and spontaneous clearance of hepatitis C virus. *Nature* **461** : 798-801, 2009
 - 8) Sheppard P, Kindsvogel W, Xu W *et al* : IL-28, IL-29 and their class II cytokine receptor IL-28R. *Nat Immunol* **4** : 63-68, 2003
 - 9) Kotenko SV, Gallagher G, Baurin VV *et al* : IFN- λ s mediate antiviral protection through a distinct class II cytokine receptor complex. *Nat Immunol* **4** : 69-77, 2003
 - 10) O'Brien TR : Interferon- α , interferon- λ and hepatitis C. *Nat Genet* **41** : 1048-1050, 2009
 - 11) Sakamoto N, Nakagawa M, Tanaka Y *et al* : Association of *IL28B* Variants With Response to Pegylated-Interferon Alpha Plus Ribavirin Combination Therapy Reveals Intersubgenotypic Differences Between Genotypes 2a and 2b. *J Med Virol* **83** : 871-878, 2011
 - 12) Akuta N, Suzuki F, Hirakawa M *et al* : Amino Acid Substitution in Hepatitis C Virus Core Region and Genetic Variation Near the Interleukin 28B Gene Predict Viral Response to Telaprevir with Peginterferon and Ribavirin. *Hepatology* **52** : 421-429, 2010
 - 13) Chayama K, Hayes CN, Abe H *et al* : *IL28B* But Not *ITPA* Polymorphism Is Predictive of Response to Pegylated Interferon, Ribavirin, and Telaprevir Triple Therapy in Patients With Genotype 1 Hepatitis C. *J Infect Dis* **204** : 84-93, 2011

第3章 治療効果予測因子のトピックス

A 宿主側因子
2 ITPA SNPs

東京医科歯科大学消化器内科 村川美也子
東京医科歯科大学消化器内科 中川 美奈
北海道大学消化器内科 坂本 直哉

CHECK POINTS!

- ▶ ゲノムワイド関連解析(GWAS)により、RBV 誘導性貧血と強く関連する一塩基多型(SNP)として、ITPA SNP が同定された
- ▶ ITPA SNP のマイナーアレルを有する患者は、RBV による溶血性貧血が軽度となる
- ▶ ITPA SNP は IFN による Plt 減少とも関連する
- ▶ PRG-IFN/RBV 併用療法および PEG-IFN/RBV/TRV 3 剤併用療法では、ITPA SNP は最終治療成績と関連しないが、今後開発される RBV を含む IFN free の新たなレジメにおいては、ITPA SNP が治療効果予測因子として重要になる可能性がある

C型慢性肝炎(chronic hepatitis C: CHC)に対するペグインターフェロン(peginterferon: PEG-IFN)/リバビリン(ribavirin: RBV)併用療法では、しばしばRBVによる溶血性貧血(hemolytic anemia)が問題となり、RBV減量や治療中止を余儀なくされるケースがある。2010年のゲノムワイド関連解析(genome-wide association study: GWAS)により、CHC治療における貧血と関連する一塩基多型(single nucleotide polymorphisms: SNPs)として、イノシントリホスファターゼ(inosine triphosphatase: ITPA)遺伝子座の2つのSNP(rs1127354, rs7270101)が同定された¹⁾。その後、日本人CHC患者のゲノム解析により、日本人にはrs7270101の多型は存在せず、rs1127354のみがRBV誘導性貧血と関連し、日本人の約75%がメジャーホモ接合体(CC)、23%がヘテロ接合体(CA)、2%がマイナーホモ接合体(AA)であり、日本人の3/4は貧血が起りやすいメジャーホモ接合体(CC)であると報告された²⁾。

1 ITPA SNP と溶血性貧血

ITPAはイノシン三リン酸(inosine triphosphate: ITP)をイノシン一リン酸(inosine monophosphate: IMP)に脱リン酸化する酵素であり、マイナーアレルをもつ患者(CA/AA)はITPA活性が低下/欠損している。そもそもRBVによる溶血性貧血は、赤血球に蓄積したRBVによってinosine monophosphate dehydrogenase (IMPDH)活性が抑制されることで赤血球グルタミルトランスペプチダーゼ(glutamyl transpeptidase: GTP)が減少し、それによりアデノシン三リン酸(adenosine triphosphate: ATP)レベルが低下し抗酸化ストレス作用が减弱することで溶血をきたすと考えられている。ITPAのマイナーアレルをもつ患者はITPA活性が低いため赤血球内にITPが蓄積し、GTP減少を代償することによってATPレベルの低下が抑えられ、溶血も起こりにくくなる。

ITPAマイナーアレルをもつCHC患者では、PEG-IFN/RBV併用療法早期の貧血が抑制される。筆者らの自験例でも治療開始後2週、4週時点のヘモグロビン減少はITPAマイナーアレル症例で有意に軽度であった(図1a)(2週: $P=6.6 \times 10^{-13}$, 4週: $P=3.0 \times 10^{-29}$)。この結果と関連して、RBV減量が必要になる患者の割合(図1b)³⁾、RBV減量までの期間、RBV予定投与量達成率との相関も報告されている。

一方、ITPA SNPと最終的な治療効果は関連しないとする報告が多い。その理由として、RBV投与量はsustained virological response(SVR)(持続的ウイルス学的著効)率の向上に寄与することが知られるが、後述のように貧血と血小板数(platelet count: Plt)減少が逆相関するためRBV減量の影響がインターフェロン(interferon: IFN)減量により相殺されること、また48週までのRBV総投与量では有意差が消失することな




図1 ITPA SNP と貧血および薬剤投与量

a : ITPA マイナーアリルをもつ患者はメジャーホモ接合体患者に比して PEG-IFN/RBV 併用療法開始後早期の貧血が有意に軽度であった。

b : ITPA SNP と治療 4 週時点で RBV 減量が必要となる患者の割合は有意な相関を認めたが、IFN 減量との関連は認めなかった。

(Sakamoto N, *et al.* : ITPA gene variant protects against anemia induced by pegylated interferon- α and ribavirin therapy for Japanese patients with chronic hepatitis C. *Hepatol Res* 2010 ; 40 : 1063-1071 より改変)

どが考えられている。ただし、genotype 1b・高ウイルス量以外の症例 (genotype 1b・低ウイルス量、genotype 2) においては、ITPA SNP と SVR に有意な相関が認められ ($P=0.0066$)、多変量解析でも ITPA SNP の SVR への関連がみられたことから、治療期間が短い場合は ITPA による初期の貧血が強く影響する可能性がある³⁾。

2 ITPA SNP と Plt 減少

ITPA SNP は PEG-IFN/RBV 治療中の Plt 減少とも関連することが知られる⁵⁾。貧血とは逆の相関であり、マイナーアリルをもつ患者の Plt 減少が強くなる。これは貧血が軽度なマイナーアリルでは溶血性貧血に対する代償機能としての反応性造血充進が弱くなるためと考えられているが、Plt 減少と ITPA SNP の関連は貧血とは独立しているとの報告もあり、IFN 誘導性 Plt 減少と ITPA SNP の直接の相互作用も示唆されるなど、今後の解析が待たれる。

ITPA SNP と IFN 減量との間には有意な関連は認められないが³⁾、治療前 Plt 低値の肝線維化進展例では注意が必要である。筆者らの自験例においては治療前 Plt 13 万 / μ L 未満の患者群で SVR 率の低下を認める

が、ITPA マイナーアリルをもつ患者ではメジャーホモ接合体患者と比較してさらに低い SVR 率となり、Plt 減少による IFN 減量の影響が示唆される⁴⁾。

3 次世代 C 型肝炎治療薬と ITPA SNP

2011 年、わが国でもプロテアーゼ阻害薬であるテラプレビル (telaprevir : TVR) が保険承認となり、今後の C 型肝炎 (hepatitis C) 治療は DAA (direct anti-viral agent) 製剤を中心とした多剤併用療法の時代を迎えると思われる。PEG-IFN/RBV/TRV 3 剤併用療法では患者の約 90% に貧血が生じ、貧血は副作用による治療脱落の最多の原因となっているが、3 剤併用療法においても ITPA SNP と治療初期の貧血は関連することが報告された。ただし、最近の報告では PEG-IFN/RBV 併用療法と同様に SVR との関連は認められず、ITPA SNP は PEG-IFN/RBV/TRV 3 剤併用療法の治療効果予測因子とはならないとされている⁶⁾。

しかしながら、現在、IFN free の DAAs 併用療法のレジメについても様々な治験が進行中であるが、RBV の併用は IFN 製剤と独立した抗ウイルス効果、再燃防止効果が認められていることから、今後も RBV の重要性は残ると考えられる。従来の IFN 製剤

をベースとした治療では ITPA SNP は SVR と関連しないが、IFN free の RBV 併用 DAA 療法が用いられた場合には、ITPA SNP が SVR の予測因子として重要な役割を果たす可能性がある。今後の解析に期待される。

4 おわりに

RBV は再発予防の治療に効果的であり、総投与量、予定投与量達成率と SVR の間に関連が認められている。したがって、貧血の起こりにくい ITPA マイナーアレルをもつ症例では、十分な RBV 投与が望ましい。また、メジャーホモ接合体症例であっても RBV を全治療期間で継続し、総投与量を確保する工夫が必要である。貧血のハイリスク患者(高齢、治療前ヘモグロビン低値、クレアチニンクリアランス低下例等)や肝線維化進行例(治療前 Plt 低値)においては、特に治療前 ITPA SNP の評価が有用であり、適切な薬剤投与量の設定やこまめな血球減少のモニタリングを行うことによって、より高率に SVR を得ることが可能となる。

今後、IFN free の治療が主流となった場合には、ITPA SNP の有用性はさらに増すものと考えられる。他

の治療効果予測因子と合わせて用いることによって、より適切なテーラーメイド医療に繋がると期待される。

文献

- 1) Fellay J, *et al.*: ITPA gene variants protect against anemia in patients treated for chronic hepatitis C. *Nature* 2010; **464**: 405-408
- 2) Ochi H, *et al.*: ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy—a genome-wide study of Japanese HCV patients. *Gastroenterology* 2010; **139**: 1190-1197
- 3) Sakamoto N, *et al.*: ITPA gene variant protects against anemia induced by pegylated interferon- α and ribavirin therapy for Japanese patients with chronic hepatitis C. *Hepatol Res* 2010; **40**: 1063-1071
- 4) Nakagawa M, *et al.*: Association of ITPA gene variation and serum ribavirin concentration with decline in blood cell concentrations during pegylated interferon- α plus ribavirin therapy for chronic hepatitis C. *Hepatology International* (Published on line: 21 March 2012)
- 5) Tanaka Y, *et al.*: Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. *Hum Mol Genet* 2011; **20**: 3507-3516
- 6) Chayama K, *et al.*: IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. *J Infect Dis* 2011; **204**: 84-93

Soluble MICA and a *MICA* Variation as Possible Prognostic Biomarkers for HBV-Induced Hepatocellular Carcinoma

Vinod Kumar^{1,2*}, Paulisally Hau Yi Lo¹, Hiromi Sawai³, Naoya Kato⁴, Atsushi Takahashi², Zhenzhong Deng¹, Yuji Urabe¹, Hamdi Mbarek¹, Katsushi Tokunaga³, Yasuhito Tanaka⁵, Masaya Sugiyama⁶, Masashi Mizokami⁶, Ryosuke Muroyama⁴, Ryosuke Tateishi⁷, Masao Omata⁷, Kazuhiko Koike⁷, Chizu Tanikawa¹, Naoyuki Kamatani², Michiaki Kubo², Yusuke Nakamura¹, Koichi Matsuda¹

1 Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan, **2** Center for Genomic Medicine, The Institute of Physical and Chemical Research (RIKEN), Kanagawa, Japan, **3** Department of Human Genetics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, **4** Unit of Disease Control Genome Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan, **5** Department of Clinical Molecular Informative Medicine, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan, **6** The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Chiba, Japan, **7** Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

Abstract

MHC class I polypeptide-related chain A (MICA) molecule is induced in response to viral infection and various types of stress. We recently reported that a single nucleotide polymorphism (SNP) rs2596542 located in the *MICA* promoter region was significantly associated with the risk for hepatitis C virus (HCV)-induced hepatocellular carcinoma (HCC) and also with serum levels of soluble MICA (sMICA). In this study, we focused on the possible involvement of MICA in liver carcinogenesis related to hepatitis B virus (HBV) infection and examined correlation between the *MICA* polymorphism and the serum sMICA levels in HBV-induced HCC patients. The genetic association analysis revealed a nominal association with an SNP rs2596542; a G allele was considered to increase the risk of HBV-induced HCC ($P = 0.029$ with odds ratio of 1.19). We also found a significant elevation of sMICA in HBV-induced HCC cases. Moreover, a G allele of SNP rs2596542 was significantly associated with increased sMICA levels ($P = 0.009$). Interestingly, HCC patients with the high serum level of sMICA (>5 pg/ml) exhibited poorer prognosis than those with the low serum level of sMICA (≤ 5 pg/ml) ($P = 0.008$). Thus, our results highlight the importance of *MICA* genetic variations and the significance of sMICA as a predictive biomarker for HBV-induced HCC.

Citation: Kumar V, Yi Lo PH, Sawai H, Kato N, Takahashi A, et al. (2012) Soluble MICA and a *MICA* Variation as Possible Prognostic Biomarkers for HBV-Induced Hepatocellular Carcinoma. PLoS ONE 7(9): e44743. doi:10.1371/journal.pone.0044743

Editor: Erica Villa, University of Modena & Reggio Emilia, Italy

Received: May 3, 2012; **Accepted:** August 7, 2012; **Published:** September 14, 2012

Copyright: © 2012 Kumar et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was conducted as a part of the BioBank Japan Project that was supported by the Ministry of Education, Culture, Sports, Science and Technology of the Japanese government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: koichima@ims.u-tokyo.ac.jp

Introduction

Hepatocellular carcinoma (HCC) reveals a very high mortality rate that is ranked the third among all cancers in the world [1]. HCC is known to develop in a multistep process which has been related to various risk factors such as genetic factors, environment toxins, alcohol and drug abuse, autoimmune disorders, elevated hepatic iron levels, obesity, and hepatotropic viral infections [2]. Among them, chronic infection with hepatitis B virus (HBV) is one of the major etiological factors for developing HCC with considerable regional variations ranging from 20% of HCC cases in Japan to 65% in China [3].

Interestingly, clinical outcome after the exposure to HBV considerably varies between individuals. The great majority of individuals infected with HBV spontaneously eliminate the viruses, but a subset of patients show the persistent chronic hepatitis B infection (CHB), and then progresses to liver cirrhosis and HCC through a complex interplay between multiple genetic and

environmental factors [4]. In this regard, genome wide association studies (GWAS) using single nucleotide polymorphisms (SNPs) have highlighted the importance of genetic factors in the pathogenesis of various diseases including CHB as well as HBV-induced HCC [5,6,7,8,9,10,11,12,13]. Recently, we identified a genetic variant located at 4.7 kb upstream of the *MHC class I polypeptide-related chain A (MICA)* gene to be strongly associated with hepatitis C virus (HCV)-induced HCC development [14].

MICA is highly expressed on viral-infected cells or cancer cells, and acts as ligand for NKG2D to activate antitumor effects of Natural killer (NK) cells and CD8⁺ T cells [15,16]. Our previous results indicated that a G allele of SNP rs2596542 was significantly associated with the lower cancer risk and the higher level of soluble MICA (sMICA) in the serum of HCV-induced HCC patients, demonstrating the possible role of MICA as a tumor suppressor. However, elevation of serum sMICA was shown to be associated with poor prognosis in various cancer patients [17,18,19,20].

Matrix metalloproteinases (MMPs) can cleave MICA at a transmembrane domain [21] and release sMICA proteins from cells. Since sMICA was shown to inhibit the antitumor effects of NK cells and CD8⁺ T cells by reduction of their affinity to binding to target cells [22,23], the effect of MICA in cancer cells would be modulated by the expression of MMPs. To elucidate the role of MICA in HBV-induced hepatocellular carcinogenesis, we here report analysis of the *MICA* polymorphism and serum sMICA level in HBV-induced HCC cases.

Materials and Methods

Study participants

The demographic details of study participants are summarized in Table 1. A total of 181 HCC cases, 597 CHB patients, and 4,549 non-HBV controls were obtained from BioBank Japan that was initiated in 2003 with the funding from the Ministry of Education, Culture, Sports, Science and Technology, Japan [24]. In the Biobank Japan Project, DNA and serum of patients with 47 diseases were collected through collaborating network of 66 hospitals throughout Japan. List of participating hospitals is shown in the following website (http://biobankjp.org/plan/member_hospital.html). A total of 226 HCC cases, 102 CHB patients, and 174 healthy controls were additionally obtained from the University of Tokyo. The diagnosis of chronic hepatitis B was conducted on the basis of HBsAg-seropositivity and elevated serum aminotransferase levels for more than six months according to the guideline for diagnosis and treatment of chronic hepatitis (The Japan Society of Hepatology, <http://www.jsh.or.jp/medical/guidelines/index.html>). Control Japanese DNA samples (n = 934) were obtained from Osaka-Midosuji Rotary Club, Osaka, Japan. All HCC patients were histopathologically diagnosed. Overall survival was defined as the time from blood sampling for sMICA test to the date of death due to HCC. Patients who were alive on the date of last follow-up were censored on that date. All participants provided written informed consent. This research project was approved by the ethics committee of the University of Tokyo and the ethics committee of RIKEN. All clinical assessments and specimen collections were conducted according to Declaration of Helsinki principles.

SNP genotyping

Genotyping platforms used in this study were shown in Table 1. We genotyped 181 HCC cases and 5,483 non-HBV control samples using either Illumina Human Hap610-Quad or Human Hap550v3. The other samples were genotyped at SNP rs2596542

by the Invader assay system (Third Wave Technologies, Madison, WI).

MICA variable number tandem repeat (VNTR) locus genotyping

Genotyping of the *MICA* VNTR locus in 176 HBV-induced HCC samples was performed using the primers reported previously by the method recommended by Applied Biosystems (Foster City, CA) [14]. Briefly, the 5' end of forward primer was labeled with 6-FAM, and reverse primer was modified with GTGTCTT non-random sequence at the 5' end to promote Plus A addition. The PCR products were mixed with Hi-Di Formamide and GeneScan-600 LIZ size standard, and separated by GeneScan system on a 3730xl DNA analyzer (Applied Biosystems, Foster City, CA). GeneMapper software (Applied Biosystems, Foster City, CA) was employed to assign the repeat fragment size (Figure S1).

Quantification of soluble MICA

We obtained serum samples of 111 HBV-positive HCC samples, 129 HCV-positive HCC samples, and 60 non-HBV controls from Biobank Japan. Soluble MICA levels were measured by sandwich enzyme-linked immunosorbent assay, as described in the manufacturer's instructions (R&D Systems, Minneapolis, MN).

Statistical analysis

The association between an SNP rs2596542 and HBV-induced HCC was tested by Cochran-Armitage trend test. The Odds ratios were calculated by considering a major allele as a reference. Statistical comparisons between genotypes and sMICA levels were performed by Kruskal-Wallis test (if more than two classes for comparison) or Wilcoxon rank test using R. Overall survival rate of the patients was analyzed by Kaplan-Meier method in combination with log-rank test with SPSS 20 software. The period for the survival analysis was calculated from the date of blood sampling to the recorded date of death or the last follow-up date. Differences with a P value of <0.05 were considered statistically significant.

Results

Association of SNP rs2596542 with HBV-induced HCC

In order to examine the effect of rs2596542 genotypes on the susceptibility to HBV-induced HCC, a total of 407 HCC cases and 5,657 healthy controls were genotyped. The Cochran Armitage trend test of the data revealed a nominal association

Table 1. Demographic details of subjects analyzed.

Subjects	Source	Genotyping platform	Number of Sample	Female (%)	Age (mean \pm sd)
Liver Cancer	BioBank Japan	Illumina Human Hap610-Quad	181	17.9	62.94 \pm 9.42
	University of Tokyo	Invader assay	226		
Control	BioBank Japan	Illumina Human Hap550v3	4549	47.95	55.19 \pm 12.5
	Osaka**	Illumina Human Hap550v3	934		
	University of Tokyo	Invader assay	174		
Chronic hepatitis B*	BioBank Japan	Invader assay	597	45.66	61.31 \pm 12.6
	University of Tokyo	Invader assay	102		

*Chronic hepatitis B patients without liver cirrhosis and liver cancer during enrollment.

**Healthy volunteers from Osaka Midosuji Rotary Club, Osaka, Japan.

doi:10.1371/journal.pone.0044743.t001

between HBV-induced HCC and rs2596542 in which a risk allele G was more frequent among HBV-induced HCC cases than an A allele ($P=0.029$, OR = 1.19, 95% CI: 1.02–1.4; Table 2). To further investigate the effect of rs2596542 on the progression from CHB to HBV-induced HCC, we genotyped a total of 699 CHB cases without HCC. Although the progression risk from CHB to HBV-induced HCC was not statistically significant with rs2596542 ($P=0.197$ by the Cochran Armitage trend test with an allelic OR = 1.3 (0.94–1.36); Table 2), we found a similar trend of association in which the frequency of a risk-allele G was higher among HBV-induced HCC patients than that of CHB subjects. Since we previously revealed that an A allele was associated with a higher risk of HCV-induced HCC with OR of 1.36 [14], the rs2596542 alleles that increased the risk of HCC were opposite in HBV-induced HCC and HCV-induced HCC.

Soluble MICA levels are associated with SNP rs2596542

We subsequently performed measurement of soluble MICA (sMICA) in serum samples using the ELISA method in 176 HBV-positive HCC cases and 60 non-HBV controls. Nearly 30% of the HBV-induced HCC cases revealed the serum sMICA level of >5 pg/ml (defined as high) while the all control individuals except one showed that of ≤ 5 pg/ml (defined as low) ($P=4.5 \times 10^{-6}$; Figure 1A). Then, we examined correlation between SNP rs2596542 genotypes and serum sMICA levels in HBV-positive HCC cases. Interestingly, rs2596542 genotypes were significantly associated with serum sMICA levels ($P=0.009$; Figure 1B); 39% of individuals with the GG genotype and 20% of those with the AG genotype were classified as high for serum sMICA, but only 11% of those with the AA genotype were classified as high (AA+AG vs GG; $P=0.003$) (Figure 1B). These findings were similar with our previous reports in which a G allele was associated with higher serum sMICA levels in HCV-induced HCC patients [14].

Negative association of variable number of tandem repeat (VNTR) with sMICA level

The *MICA* gene harbors a VNTR locus in exon 5 that consists of 4, 5, 6, or 9 repeats of GCT as well as a G nucleotide insertion into a five-repeat allele (referred as A4, A5, A6, A9, and A5.1, respectively). The insertion of G (A5.1) causes a premature translation termination and results in loss of a transmembrane domain, which may produce the shorter form of the MICA protein that is likely be secreted into serum [25]. However, the association of this VNTR locus with serum sMICA level was controversial among studies [14,26,27,28]. Therefore, we examined the association between the VNTR locus and sMICA level in HBV-induced HCC patients, and found no significant association (Figure S1 and S2), concordant with our previous report for HCV-induced HCC patients [14].

Soluble MICA levels are associated with survival of HCC patients

In order to evaluate the prognostic significance of serum sMICA levels in HCC patients, we performed survival analysis of HCC patients. A total of 111 HBV-infected HCC patients and 129 HCV-infected HCC patients were included in this analysis. The mean survival period for HBV- and HCV-infected patients with less than 5 pg/ml of serum sMICA were 67.1 months (95% CI: 61.1–73.1, $n=83$), and 58.2 months (95% CI: 51.4–65.0, $n=85$), respectively. On the other hand, for patients with more than 5 pg/ml of serum sMICA, the mean survival periods were 47.8 months (95% CI: 34.8–30.9, $n=28$) for HBV-induced HCC patients and 59.5 months (95% CI: 51.9–67.1, $n=44$) for HCV-induced HCC patients. The Kaplan-Maier analysis and log-rank test indicated that among HBV-induced HCC subjects, the patients in the high serum sMICA group showed a significantly shorter survival than those in the low serum sMICA ($P=0.008$; Figure 2). In addition, we performed multi-variate analysis to test whether sMICA is an independent prognostic factor by including age and gender as covariates. The results revealed significant association of sMICA levels with overall survival ($P=0.017$) but not with age and gender (Table S1). However, we found no association between the serum sMICA level and the overall survival in the HCV-induced HCC subjects ($P=0.414$; Figure S3). Taken together, our findings imply the distinct roles of the *MICA* variation and sMICA between HBV- and HCV-induced hepatocellular carcinogenesis.

Vascular invasion in HBV-related HCC patients is associated with soluble MICA levels

Since sMICA levels were associated with the overall survival of HBV-related HCC patients, we tested whether sMICA levels affect survival through modulating invasive properties of tumors or size of the tumors. We tested the association between sMICA levels and vascular invasion in 35 HBV-related HCC cases, among whom 7 cases were positive and 21 cases were negative for vascular invasion. We found significant association between sMICA levels and vascular invasion (Figure 3; $P=0.014$) in which 7 cases with positive vascular invasion showed high levels of sMICA (mean = 54 pg/ml) than 21 cases without vascular invasion (mean = 7.51 pg/ml). However, we found no association between tumor size and sMICA levels ($P=0.56$; data not shown). These results suggest that sMICA may reduce the survival of HBV-related HCC patients by affecting the invasive properties of tumors.

Discussion

Several mechanisms such as HBV-genome integration into host chromosomal DNA [29] and effects of viral proteins including HBx [30] are shown to contribute to development and progression of HCC, while the immune cells such as NK and T cells function as key antiviral and antitumor effectors. MICA protein has been

Table 2. Association between HCC and rs2596542.

SNP	Comparison	Chr	Locus	Case MAF	Control MAF	<i>P</i> *	OR*	95% CI
rs2596542	HCC vs. Healthy control	6	<i>MICA</i>	0.294	0.332	0.029	1.19	1.02–1.4
rs2596542	HCC vs. CHB	6	<i>MICA</i>	0.294	0.320	0.197	1.13	0.94–1.36

Note: 407 HCC cases, 699 CHB subjects and 5,657 non-HBV controls were used in the analysis.

Chr., chromosome; MAF, minor allele frequency; OR, odds ratio for minor allele; CI, confidence interval.

*Obtained by Armitage trend test.

doi:10.1371/journal.pone.0044743.t002




Figure 1. Soluble MICA levels are associated with HBV-related HCC. (A) Correlation between soluble MICA levels and HBV-induced HCC subjects. The y-axis displays the concentration of soluble MICA in pg/ml. The number of independent samples tested in each group is shown in the x-axis. Each group is shown as a box plot and the mean values are shown in the x-axis. The difference between two groups is tested by Wilcoxon rank test. The box plots are plotted using default settings in R. (B) Correlation between soluble MICA levels and rs2596542 genotype in HBV-positive HCC subjects. The x-axis shows the genotypes at rs2596542 and y-axis display the concentration of soluble MICA in pg/ml. Each group is shown as a box plot. $P = 0.027$ and 0.013 for AA vs. GG and AA vs. AG, respectively. The association between genotypes and sMICA levels was tested by Kruskal-wallis test, whereas the difference in the sMICA levels between AA and GG is tested by Wilcoxon rank test. The box plots are plotted using default settings in R.

doi:10.1371/journal.pone.0044743.g001

considered as a stress marker of gastrointestinal epithelial cells because of its induced expression by several external stimuli such as heat, DNA damage, and viral infections [31,32,33,34]. Here,

we examined the association of rs2596542 and serum sMICA levels with HBV-induced HCC. Like in HCV-induced HCC [14], our results from ELISA revealed a significantly higher proportion




Figure 2. Kaplan-Meier curves of the patients with HBV-induced HCC. The patients were divided into two groups according to their sMICA concentration (high: >5 pg/ml and low: ≤ 5 pg/ml). Statistical difference was analyzed by log-rank test. The y-axis shows the cumulative survival probability and x-axis display the months of the patients' survival after blood sampling.

doi:10.1371/journal.pone.0044743.g002




Figure 3. Correlation between soluble MICA levels and vascular invasion in HBV-induced HCC subjects. The y-axis displays the concentration of soluble MICA in pg/ml. The number of independent samples tested in each group is shown in the x-axis. Each group is shown as a box plot and the mean values are shown in the x-axis. The difference between two groups is tested by Wilcoxon rank test. The box plots are plotted using default settings in R.

doi:10.1371/journal.pone.0044743.g003

of high serum sMICA cases (nearly 30%) in the HBV-induced HCC group, compared to non-HBV individuals (1.7%). Moreover, the serum sMICA level was significantly associated with rs2596542, but not with the copy number differences of the VNTR locus, as concordant with our previous report [14].

Several studies have already indicated the roles of sMICA as prognostic markers for different types of malignant diseases [17,18,19,20]. Therefore, it is of medical importance to test whether serum sMICA levels can be used as a prognostic marker for patients with HCC. To our best knowledge, this is the first study to demonstrate the prognostic potential of sMICA for HBV-positive HCC patients; we found 19.3 months of improvement in survival among patients carrying less than 5 pg/ml of serum sMICA, compared to those having more than 5 pg/ml.

On the contrary, we found no significant correlation between sMICA levels and the prognosis of HCV-induced HCC cases. These opposite effects of *MICA* variation could be explained by the following mechanism. The individuals who carry the G allele would express high levels of membrane-bound MICA upon HCV infection and thus lead to the activation of immune cells against virus infected cells. On one hand, HBV infection results in increased expression of membrane-bound MICA as well as MMPs through viral protein HBx [35], which would result in the elevation of sMICA and the reduction of membrane-bound MICA. Since sMICA could block CD8+T cells, NK-CTL, and NK cells, higher sMICA would cause the inactivation of immune surveillance system against HBV infected cells. In other words, HBV may use this strategy to evade immune response and hence, higher levels of sMICA could be associated with lower survival rate among HBV-associated HCC. On the other hand, since HCV is not known to induce the cleavage of membrane bound MICA, individuals with low level membrane bound MICA expression (carriers of rs2596542-allele A) could be inherently susceptible for HCV-induced HCC. Thus, HBx-mediated induction of MMPs could partially explain the intriguing contradictory effect of MICA between HBV-induced HCC and HCV-induced HCC. Since we observed significant correlation of sMICA levels with vascular invasion, it may be the case that high levels of sMICA cause poor prognosis of HBV-related HCC cases by making tumors more aggressive and invasive. However it is important in future to determine the ratio of membrane-bound MICA to sMICA in case of HCV- and HBV-related HCC.

Interestingly, the immune therapy against melanoma patients induced the production of auto-antibodies against MICA [36]. Anti-MICA antibodies would exert antitumor effects through antibody-dependent cellular cytotoxicity against cells expressing membrane-bound MICA and/or activation of NK cells by inhibiting the sMICA-NKG2D interaction. However, further studies are necessary, using well-defined HBV-related HCC

cohort, to investigate whether sMICA levels could be included as an additional factor to predict the survival rate among HBV-related HCC subjects. Taken together, our results indicate the potential of *MICA* variant and sMICA as prognostic biomarkers. Thus, MICA could be a useful therapeutic target for HBV-induced HCC.

Supporting Information

Figure S1 MICA repeat genotyping using capillary-based method. The alleles are annotated using GeneMapper software based on the size of the PCR product (185 bp = A4 allele, 188 bp = A5, 189 bp = A5.1, 191 bp = A6 and 200 bp = A9). The inset at the base of each peak shows the size of the PCR product with corresponding allele call by the software. The figure display all observed heterozygotes at A5.1 allele.

(TIF)

Figure S2 MICA VNTR alleles are not associated with soluble MICA levels. Each group is shown as a box plot. The difference in the sMICA values among each group is tested by Wilcoxon rank test. The box plots are plotted using default settings in R.

(TIF)

Figure S3 Kaplan-Meier curves of the patients with HCV-induced HCC. The patients were divided into two groups according to their sMICA concentration (<5 pg/ml or >5 pg/ml). Statistical difference was analyzed by log-rank test. The y-axis shows the cumulative survival probability and x-axis display the months of the patients survival after blood sampling.

(TIF)

Table S1 Clinical parameters of HBV-related HCC patients available for prognostic analyses.

(XLS)

Acknowledgments

We would like to thank all the patients and the members of the Rotary Club of Osaka-Midosuji District 2660 Rotary International in Japan, who donated their DNA for this work. We also thank Ayako Matsui and Hiroe Tagaya (the University of Tokyo), and the technical staff of the Laboratory for Genotyping Development, Center for Genomic Medicine, RIKEN for their technical support.

Author Contributions

Conceived and designed the experiments: VK KM YN. Performed the experiments: VK PHL YU HM ZD. Analyzed the data: VK PHL CT RM. Contributed reagents/materials/analysis tools: YN NK AT MK HS KT YT MS MM RT MO KK NK. Wrote the paper: VK PHL KM YN.

References

- Kew MC (2010) Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. *Pathol Biol (Paris)* 58: 273–277.
- Sherman M (2010) Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. *Semin Liver Dis* 30: 3–16.
- Perz J, Armstrong G, Farrington L, Hutin Y, Bell B (2006) The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. *J Hepatol* 45: 529–538.
- Chen CJ, Chen DS (2002) Interaction of hepatitis B virus, chemical carcinogen, and genetic susceptibility: multistage hepatocarcinogenesis with multifactorial etiology. *Hepatology* 36: 1046–1049.
- Cui R, Okada Y, Jang SG, Ku JL, Park JG, et al. (2011) Common variant in 6q26–q27 is associated with distal colon cancer in an Asian population. *Gut* 60: 799–805.
- Kumar V, Matsuo K, Takahashi A, Hosono N, Tsunoda T, et al. (2011) Common variants on 14q32 and 13q12 are associated with DLBCL susceptibility. *J Hum Genet* England. pp. 436–439.
- Cui R, Kamatani Y, Takahashi A, Usami M, Hosono N, et al. (2009) Functional variants in ADH1B and ALDH2 coupled with alcohol and smoking synergistically enhance esophageal cancer risk. *Gastroenterology* 137: 1768–1775.
- Urabe Y, Tanikawa C, Takahashi A, Okada Y, Morizono T, et al. (2012) A genome-wide association study of nephrolithiasis in the Japanese population identifies novel susceptible loci at 5q35.3, 7p14.3 and 13q14.1. *PLOS Genet* 8(3): e1002541.
- Tanikawa C, Urabe Y, Matsuo K, Kubo M, Takahashi A, et al. (2012) A genome-wide association study identifies two susceptibility loci for duodenal ulcer in the Japanese population. *Nat Genet* 44(4): 430–434.

10. Hata J, Matsuda K, Ninomiya T, Yonemoto K, Matsushita T, et al. (2007) Functional SNP in an Sp1-binding site of AGTRL1 gene is associated with susceptibility to brain infarction. *Hum Mol Genet* 16: 630–639.
11. Kamatani Y, Wattanapokayakit S, Ochi H, Kawaguchi T, Takahashi A, et al. (2009) A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. *Nat Genet* 41: 591–595.
12. Mbarek H, Ochi H, Urabe Y, Kumar V, Kubo M, et al. (2011) A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population. *Human Molecular Genetics* 20: 3884–3892.
13. Zhang H, Zhai Y, Hu Z, Wu C, Qian J, et al. (2010) Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. *Nat Genet* 42: 755–758.
14. Kumar V, Kato N, Urabe Y, Takahashi A, Muroyama R, et al. (2011) Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. *Nature genetics* 43: 455–458.
15. Jinushi M, Takehara T, Tatsumi T, Kanto T, Groh V, et al. (2003) Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. *Int J Cancer* 104: 354–361.
16. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, et al. (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. *Science* 285: 727–729.
17. Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A, et al. (2006) Soluble MICA in malignant diseases. *Int J Cancer* 118: 684–687.
18. Nüchel H, Switala M, Sellmann L, Horn PA, Dürig J, et al. (2010) The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia. *Leukemia* 24: 1152–1159.
19. Tamaki S, Sanefuzi N, Kawakami M, Aoki K, Imai Y, et al. (2008) Association between soluble MICA levels and disease stage IV oral squamous cell carcinoma in Japanese patients. *Hum Immunol* 69: 88–93.
20. Li K, Mandai M, Hamanishi J, Matsumura N, Suzuki A, et al. (2009) Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. *Cancer Immunol Immunother* 58: 641–652.
21. Salih H, Rammensee H, Steinle A (2002) Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. *J Immunol* 169: 4098–4102.
22. Groh V, Wu J, Yee C, Spies T (2002) Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. *Nature* 419: 734–738.
23. Jinushi M, Takehara T, Tatsumi T, Hiramatsu N, Sakamori R, et al. (2005) Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. *J Hepatol* 43: 1013–1020.
24. Nakamura Y (2007) The BioBank Japan Project. *Clin Adv Hematol Oncol* 5: 696–697.
25. Ota M, Katsuyama Y, Mizuki N, Ando H, Furihata K, et al. (1997) Trinucleotide repeat polymorphism within exon 5 of the MICA gene (MHC class I chain-related gene A): allele frequency data in the nine population groups Japanese, Northern Han, Hui, Uyghur, Kazakhstan, Iranian, Saudi Arabian, Greek and Italian. *Tissue Antigens* 49: 448–454.
26. Tamaki S, Sanefuzi N, Ohgi K, Imai Y, Kawakami M, et al. (2007) An association between the MICA-A5.1 allele and an increased susceptibility to oral squamous cell carcinoma in Japanese patients. *J Oral Pathol Med* 36: 351–356.
27. Tamaki S, Kawakami M, Yamanaka Y, Shimomura H, Imai Y, et al. (2009) Relationship between soluble MICA and the MICA A5.1 homozygous genotype in patients with oral squamous cell carcinoma. *Clin Immunol* 130: 331–337.
28. Lü M, Xia B, Ge L, Li Y, Zhao J, et al. (2009) Role of major histocompatibility complex class I-related molecules A*5.1 allele in ulcerative colitis in Chinese patients. *Immunology* 128: e230–236.
29. Bonilla Guerrero R, Roberts LR (2005) The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma. *J Hepatol* 42: 760–777.
30. Bouchard MJ, Schneider RJ (2004) The enigmatic X gene of hepatitis B virus. *J Virol* 78: 12725–12734.
31. Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, et al. (1996) Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. *Proc Natl Acad Sci U S A* 93: 12445–12450.
32. Groh V, Steinle A, Bauer S, Spies T (1998) Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. *Science* 279: 1737–1740.
33. Groh V, Rhinehart R, Randolph-Habecker J, Topp M, Riddell S, et al. (2001) Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. *Nat Immunol* 2: 255–260.
34. Gasser S, Orsulic S, Brown EJ, Raulet DH (2005) The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. *Nature* 436: 1186–1190.
35. Lara-Pezzi E, Gomez-Gavero MV, Galvez BG, Mira E, Iniguez MA, et al. (2002) The hepatitis B virus X protein promotes tumor cell invasion by inducing membrane-type matrix metalloproteinase-1 and cyclooxygenase-2 expression. *J Clin Invest* 110: 1831–1838.
36. Jinushi M, Hodi F, Dranoff G (2006) Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. *Proc Natl Acad Sci U S A* 103: 9190–9195.

A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region

Yuji Urabe^{1,2}, Hidenori Ochi², Naoya Kato⁴, Vinod Kumar^{1,3}, Atsushi Takahashi³, Ryosuke Muroyama⁴, Naoya Hosono³, Motoyuki Otsuka⁵, Ryosuke Tateishi⁵, Paulisally Hau Yi Lo¹, Chizu Tanikawa¹, Masao Omata⁵, Kazuhiko Koike⁵, Daiki Miki², Hiromi Abe², Naoyuki Kamatani³, Joji Toyota⁶, Hiromitsu Kumada⁷, Michiaki Kubo³, Kazuaki Chayama², Yusuke Nakamura^{1,3}, Koichi Matsuda^{1,*}

¹Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; ²Department of Medical and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan; ³Center for Genomic Medicine, The Institute of Physical and Chemical Research (RIKEN), Kanagawa, Japan; ⁴Unit of Disease Control Genome Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; ⁵Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; ⁶Department of Gastroenterology, Sapporo Kosei General Hospital, Hokkaido, Japan; ⁷Department of Hepatology, Toranomon Hospital, Tokyo, Japan

Background & Aims: We performed a genome-wide association study (GWAS) of hepatitis C virus (HCV)-induced liver cirrhosis (LC) to identify predictive biomarkers for the risk of LC in patients with chronic hepatitis C (CHC).

Methods: A total of 682 HCV-induced LC cases and 1045 CHC patients of Japanese origin were genotyped by Illumina Human Hap 610-Quad bead Chip.

Results: Eight SNPs which showed possible associations ($p < 1.0 \times 10^{-5}$) at the GWAS stage were further genotyped using 936 LC cases and 3809 CHC patients. We found that two SNPs within the major histocompatibility complex (MHC) region on chromosome 6p21, rs910049 and rs3135363, were significantly associated with the progression from CHC to LC ($p_{\text{combined}} = 9.15 \times 10^{-11}$ and 1.45×10^{-10} , odds ratio (OR) = 1.46 and 1.37, respectively). We also found that *HLA-DQA1*0601* and *HLA-DRB1*0405* were associated with the progression from CHC to LC ($p = 4.53 \times 10^{-4}$ and 1.54×10^{-4} with OR = 2.80 and 1.45, respectively). Multiple logistic regression analysis revealed that rs3135363, rs910049, and *HLA-DQA1*0601* were independently associated with the risk of HCV-induced LC. In addition, individ-

uals with four or more risk alleles for these three loci have a 2.83-fold higher risk for LC than those with no risk allele, indicating the cumulative effects of these variations.

Conclusions: Our findings elucidated the crucial roles of multiple genetic variations within the MHC region as prognostic/predictive biomarkers for CHC patients.

© 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Introduction

Two million people in Japan and 210 million people worldwide are estimated to be infected with the hepatitis C virus (HCV), which is known to be a major cause of chronic viral liver disease [1]. Patients with chronic hepatitis C (CHC) usually exhibit mild inflammatory symptoms, but are at a significantly high risk for developing liver cirrhosis (LC) and hepatocellular carcinoma [2]. More than 400,000 people at present suffer from LC, which is ranked as the 9th major cause of death in Japan. In addition, liver cancer causes approximately 32,000 deaths per year, making it the 4th most common cause of death from malignant diseases. Thus, HCV-related diseases are important public health problems [3].

Clinical outcomes after the exposure to HCV vary enormously among individuals. Approximately 70% of infected persons will develop chronic hepatitis [4], and about 20–30% of CHC patients will develop cirrhosis, but others can remain asymptomatic for decades [2]. The annual death rate of patients with decompensated cirrhosis is as high as 15–30% [5]. Moreover, more than 7% of LC patients develop hepatocellular cancer in Japan and Taiwan, while the frequencies are less than 1.6% among other ethnic groups [6,7]. These inter-individual and inter-ethnic differences have been attributed to various factors such as viral genotypes,

Keywords: Genome-wide association study; Hepatitis C virus; Liver cirrhosis; Major histocompatibility complex.

Received 22 April 2012; received in revised form 15 December 2012; accepted 24 December 2012

* Corresponding author. Address: Laboratory of Molecular Medicine, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato, Tokyo 108-8639, Japan. Tel.: +81 3 5449 5376; fax: +81 3 5449 5123.

E-mail address: koichima@ims.u-tokyo.ac.jp (K. Matsuda).

Abbreviations: CHC, chronic hepatitis C; GWAS, genome-wide association study; HCV, hepatitis C virus; LC, liver cirrhosis; MHC, major histocompatibility complex; OR, odds ratio; PBC, primary biliary cirrhosis; SNPs, single nucleotide polymorphisms.



ELSEVIER

Journal of Hepatology 2013 vol. xxx | xxx–xxx

Research Article

Table 1. Characteristics of samples and methods used in this study.

Stage	Source	Platform	Number of samples	Female (%)	Age, yr (mean ± SD)
GWAS					
Liver cirrhosis	BioBank Japan	Illumina Human Hap 610	682	313 (46.3)	67.1 ± 9.7
Chronic hepatitis C ^a	Hiroshima University	Illumina Human Hap 610	1045	371 (35.5)	55.2 ± 11.0
Replication					
Liver cirrhosis	Tokyo University	Invader assay	716	334 (46.8)	64.4 ± 10.4
	Hiroshima University		220	98 (44.5)	64.7 ± 8.98
Chronic hepatitis C ^a	BioBank Japan	Invader assay	1670	780 (46.8)	59.7 ± 12.6
	Hiroshima University		2139	1061 (51.8)	58.8 ± 9.20

^a Number of samples that qualified. CHC patients with severe liver fibrosis (F3 or F4) or lower platelet counts (<160,000) were excluded.

alcohol consumption, age at infection, co-infection of HIV or HBV [8–10], insulin resistance, steatosis, and metabolic syndrome [11]. Previous gene expression analyses also identified various genes associated with liver fibrosis among patients with CHC [12–14]. In addition, miRNAs such as mir-21 and mir-122 were shown to be correlated with liver fibrosis [15,16].

Currently, the genome-wide association study is the most common method to identify genetic variations associated with disease risk [17–20]. In addition, the roles of genetic factors in HCV-related diseases have been elucidated. *IL28B* is associated with spontaneous clearance of HCV [21] as well as with the clinical response to the combination therapy of pegylated interferon and ribavirin [22,23]. Recently, our group has shown that SNP rs2596542 on *MICA* [24] and SNP rs1012068 on *DEPDC5* [25] are significantly associated with HCV-induced liver cancer. Although liver cirrhosis is the major risk factor of liver cancer, a fraction of CHC patients will develop HCC without accompanying LC. Therefore, the underlying genetic background would be different between HCV-induced LC and HCV-induced HCC. Previous studies identified the association of genetic variants in *HLA-DQ/DR/B* [26–28], *2-5AS* [29], *TLR3* [30], and *PNPLA3* [31] with the risk of liver fibrosis among patients with CHC. However, a comprehensive approach for HCV-induced LC has not been conducted so far. Here we performed GWAS of HCV-induced LC to identify predictive biomarkers for the risk of LC in patients with CHC.

Materials and methods

Ethics statement

All subjects provided written informed consent. This project was approved by the ethical committees at University of Tokyo, Hiroshima University, Sapporo Kosei General Hospital, Toranomon Hospital, and Center for Genomic Medicine, Institutes of Physical and Chemical Research (RIKEN).

Study population

The characteristics of each cohort are shown in Table 1. In this study, we conducted GWAS and replication analysis on a total of 1618 HCV-induced LC and 4854 CHC patients. All subjects had abnormal levels of serum alanine transaminase for more than 6 months and were positive for both HCV antibody and serum HCV RNA. Among 1618 LC and 4854 CHC samples, 342 LC patients (21.14%) and 2997 CHC patients (61.70%) underwent liver biopsy. The remaining 1276 LC and 1857 CHC patients were diagnosed by non-invasive methods including hepatic imaging (e.g., ultrasonography, computed tomography, arteriography or magnetic resonance imaging), biochemical data (serum bilirubin, serum albumin, platelet, or prothrombin time), and the presence/absence of clinical manifestations of portal hypertension (e.g., varices, encephalopathy or ascites). The patients with CHC

or LC were recruited for this study regardless of their treatment history. We excluded from the analysis the followings CHC patients: (1) advanced liver fibrosis (F3 or F4 by New Inuyama classification) [32], (2) platelet count under 160,000 for patients without liver fibrosis staging, and (3) HBV co-infection. Characteristics of each study cohort are shown in Table 1. In brief, DNA of HCV-induced LC and CHC patients was obtained from Biobank Japan (<http://biobank.jp/>) [33], the Hiroshima Liver Study Group (<http://home.hiroshima-u.ac.jp/naika1/researchprofile/pdf/liverstudygroupe.pdf>), Toranomon Hospital, and the University of Tokyo. All subjects were of Japanese origin.

SNP genotyping

Genomic DNA was extracted from peripheral blood leukocytes using a standard method. In GWAS, we genotyped 682 LC and 1045 CHC samples using Illumina Human Hap 610-Quad bead Chip (Supplementary Fig. 1). Samples with low call rate (<0.98) were excluded from our analysis (six LC and two CHC samples). We then applied SNP quality control as follows: call rate ≥ 0.99 in LC and CHC samples, Hardy-Weinberg $p \geq 1 \times 10^{-6}$ in LC and CHC samples. Consequently, 461,992 SNPs on the autosomal chromosomes passed the quality control filters. SNPs with minor allele frequency of <0.01 in both LC and CHC samples were excluded from further analyses, considering statistical power in the replication analysis. Finally, we analyzed 431,618 SNPs in GWAS. Among the top ten SNPs showing $p < 1.0 \times 10^{-5}$, we selected nine SNPs for further analysis with LD threshold of $r^2 = 0.95$. In the replication stage, we genotyped 936 LC and 3809 CHC using multiplex PCR-based Invader assay (Third Wave Technologies).

Statistical analysis

The association of SNPs with the phenotype in the GWAS, replication stage, and combined analyses was tested by logistic regression analysis, upon adjusting for age at recruitment (continuous) and gender, by assuming additive model using PLINK [34]. In the GWAS, the genetic inflation factor λ was derived by applying logistic regressed p values for all the tested SNPs. The quantile-quantile plot was drawn using R program. The odds ratios were calculated using the non-susceptible allele as reference, unless stated otherwise. The combined analysis of GWAS and replication stage was verified by using the Mantel-Haenszel method. We set the significance threshold as follows: $p = 1 \times 10^{-5}$ in the GWAS stage (first stage) and $p = 6.25 \times 10^{-3}$ ($=0.05/8$) in the replication analysis. We considered $p < 5 \times 10^{-8}$ as threshold of GWAS significance in the combined analysis, which is the Bonferroni-corrected threshold for the number of independent SNPs genotyped in HapMap Phase II [35]. The heterogeneity across two stages was examined by using the Breslow-Day test [36]. We used Haploview software to analyze the association of haplotypes and LD values between SNPs. Quality control for SNPs was applied as follows: call rate ≥ 0.95 in LC and CHC samples, and Hardy-Weinberg $p \geq 1 \times 10^{-6}$ in CHC samples in replication stage. The statistical power was 19.51% in GWAS (the first stage) ($p = 1.00 \times 10^{-5}$), 97.98% in replication ($p = 0.05/8$), and 74.76% in the combined stage ($p = 5.00 \times 10^{-8}$) at minor allele frequency of 0.3 and OR of 1.3.

Imputation-based association analysis of HLA class I and class II alleles

We obtained a SNP or a combination of SNPs which could tag the HLA alleles in the Japanese population from a previous study [37]. Genotypes of tagging SNPs were imputed in the GWAS samples by using a Hidden Markov model programmed in MACH [38] and haplotype information from HapMap JPT samples




Fig. 1. Regional association plot at 6p21.3. (Upper panel) p Values of genotyped SNPs (circle) and imputed SNPs (cross) are plotted (as $-\log_{10} p$ value) against their physical position on chromosome 6 (NCBI Build 36). The p value for rs910049 at GWAS is represented by a purple diamond. Estimated recombination rates from HapMap JPT show the local LD structure. Inset; the color of the other SNPs indicates LD with rs3135363 according to a scale from $r^2 = 0$ to $r^2 = 1$ based on pair-wise r^2 values from HapMap JPT. (Lower panel) Gene annotations from the University of California Santa Cruz genome browser.

and 1000 genome imputation samples [39]. We applied the same SNP quality criteria as in GWAS, to select SNPs for the analysis. We employed the logistic regression analysis upon age and gender adjustment to assess the associations between HCV-induced LC and HLA alleles.

Software

For general statistical analysis, we employed R statistical environment version 2.9.1 (cran.r-project.org) or plink-1.06 (pngu.mgh.harvard.edu/~purcell/plink/). The Haploview software version 4.2 [40] was used to calculate LD and to draw Manhattan plot. Primer3 -web v0.3.0 (<http://frodo.wi.mit.edu>) web tool was used to design primers. We employed LocusZoom (<http://csg.sph.umich.edu/locuszoom/>) for regional plots. We used SNP Functional Prediction web tool for functional annotation of SNPs (<http://snpinfo.niehs.nih.gov/snpfunc.htm>) [41]. We used "Gene Expression Analysis Based on Imputed Genotypes" (<http://www.sph.umich.edu/csg/liang/imputation>) [42] for eQTL analysis. We used MACTH [43] web tool for searching potential binding sites for transcription factors (<http://www.gene-regulation.com/index.htm>).

Results

Genome-wide association study for HCV-induced liver cirrhosis

We performed a two-stage GWAS using a total of 1618 cases and 4854 controls (Supplementary Fig. 1). In the first stage, a whole genome scan was performed on 682 Japanese patients with HCV-induced LC and 1045 Japanese patients with CHC, using Illumina Human Hap 610-Quad bead Chip. The genotyping results of 431,618 single nucleotide polymorphisms (SNPs) obtained after our standard quality control were used for further analysis.

CHC patients with severe liver fibrosis (F3 or F4 according to the New Inuyama classification [32]) or lower platelet counts ($<160,000$) were excluded from the control group. As progression from CHC to LC is strongly affected by age and gender, we performed logistic regression analyses including age and gender as covariates at all tested loci in our analyses. The genetic inflation factor lambda was 1.051, indicating that there is little or no evidence of population stratification (Supplementary Fig. 2A). Although no SNPs cleared the GWAS significance threshold ($p < 5 \times 10^{-8}$) at the first stage, we selected ten candidate SNPs showing suggestive association of $p < 1 \times 10^{-5}$ (Supplementary Fig. 2B and Supplementary Table 1). After excluding SNP rs6891116 due to almost absolute linkage with SNP rs10252674 ($r^2 = 0.99$), the remaining nine SNPs were further genotyped using an independent cohort, consisting of 936 LC and 3809 CHC cases, by multiplex PCR-based Invader assay as the second stage. We could successfully obtain genotype results for eight SNPs after the QC filter (call rate ≥ 0.95 in LC and CHC samples, Hardy-Weinberg of $p \geq 1 \times 10^{-6}$ in CHC samples). The logistic regression analysis adjusted by age and gender revealed that five SNPs on chromosome 6q21.3 indicated a significant association with progression from CHC to LC after the Bonferroni correction ($p < 0.05/8 = 6.25 \times 10^{-3}$, Supplementary Table 2). A meta-analysis of the two stages with a fixed-effects model revealed that all of the five SNPs significantly associated with progression from CHC to LC (p values of 9.15×10^{-11} – 1.28×10^{-8} with odds ratios (OR) of 1.30–1.46, Fig. 1 and Table 2). These five SNPs were located in the HLA class II region and were in strong linkage disequilibrium with each other (D' > 0.75 , Sup-

Research Article

Table 2. Summary of GWAS and replication analyses.

SNP	Stage	Allele (1/2)	Gene	Liver cirrhosis				Chronic hepatitis C				OR (95% CI) ^b	p value ^c	p value _{het} ^d
				11	12	22	RAF ^a	11	12	22	RAF ^a			
rs910049														
	GWAS	a/g	<i>C6orf10</i>	24	217	435	0.196	25	224	794	0.131	1.73 (1.40-2.15)	5.39 × 10 ⁻⁷	
	Replication		(6p21.3)	38	259	631	0.180	66	952	2790	0.142	1.37 (1.20-1.58)	7.59 × 10 ⁻⁶	
	Combined ^e											1.46 (1.28-1.62)	9.15 × 10 ⁻¹¹	0.075
rs3817963														
	GWAS	a/g	<i>BTNL2</i>	92	343	241	0.390	101	437	505	0.306	1.53 (1.29-1.81)	9.50 × 10 ⁻⁷	
	Replication		(6p21.3)	130	395	395	0.356	409	1573	1816	0.315	1.22 (1.10-1.36)	2.66 × 10 ⁻⁴	
	Combined ^e											1.30 (1.18-1.42)	1.28 × 10 ⁻⁸	0.029
rs9405098														
	GWAS	a/g	No gene	75	293	308	0.328	70	365	608	0.242	1.54 (1.30-1.84)	1.10 × 10 ⁻⁶	
	Replication		(6p21.3)	100	361	462	0.304	249	1429	2129	0.253	1.30 (1.16-1.46)	5.64 × 10 ⁻⁶	
	Combined ^e											1.37 (1.23-1.50)	1.04 × 10 ⁻¹⁰	0.105
rs3135363														
	GWAS	c/t	No gene	35	258	383	0.757	89	447	507	0.700	1.58 (1.32-1.90)	7.89 × 10 ⁻⁷	
	Replication		(6p21.3)	73	322	540	0.750	389	1486	1929	0.702	1.30 (1.16-1.46)	7.94 × 10 ⁻⁶	
	Combined ^e											1.37 (1.24-1.51)	1.45 × 10 ⁻¹⁰	0.069
rs3129860														
	GWAS	a/g	No gene	58	294	324	0.303	57	348	638	0.221	1.55 (1.29-1.82)	6.45 × 10 ⁻⁶	
	Replication		(6p21.3)	88	339	507	0.276	208	1341	2246	0.231	1.28 (1.14-1.44)	2.53 × 10 ⁻⁵	
	Combined ^e											1.36 (1.22-1.49)	1.07 × 10 ⁻⁹	0.085

1618 (682 in GWAS and 936 in replication) liver cirrhosis and 4854 (1045 in GWAS and 3809 in replication) chronic hepatitis C samples were analyzed.

^aRAF, risk allele frequency.

^bOR, odds ratios; CI, confidence interval.

^cp Values obtained by logistic regression analysis adjusted for age and gender under additive model.

^dp Values of heterogeneities (Phet) across three stages were examined by using the Breslow-Day test.

^eCombined odds ratio and p values for independence test were calculated by Mendel-hauzen and Laird method in the meta-analysis.

plementary Fig. 3). To further evaluate the effect of each variation on the progression from CHC to LC, we performed multiple logistic regression analyses. As a result, rs910049 (p of 1.91×10^{-3} with OR of 1.25) and rs3135363 (p of 1.49×10^{-4} with OR of 1.23) remained significantly associated with the progression risk from CHC to LC, while the remaining three SNPs failed to show significant associations ($p > 0.05$) (Supplementary Table 3). Thus, two SNPs, rs910049 and rs3135363, seem to be independent risk factors for HCV-induced LC.

Since reduced platelet level is associated with a poor prognosis among CHC patients [44] we excluded patients with platelet level of less than 160,000 from CHC groups to increase the risk of type 2 error in this study. We also conducted the analysis using only CHC patients diagnosed with liver biopsy. As a result, both SNPs reached genome-wide significance ($p < 5 \times 10^{-8}$), although the associations were reduced due to the smaller sample size (Supplementary Table 4).

Subgroup analyses, stratified by IFN treatment status, amount of alcohol consumption, and gender, were also performed, since these factors were shown to be associated with the prognosis of CHC patients [45–47]. A total of 334 LC patients (35.83%) and 2325 CHC (82.4%) were treated with IFN therapy. Although the frequency of IFN treatment was different between CHC and LC groups, these variations associated with the LC risk regardless of IFN treatment as well as gender and alcohol consumption (Supplementary Fig. 4A–C). When we included these factors as covariates, the association of these variations with HCV-induced LC was sustained, with OR of 1.48 and 1.56, and SNP rs3135363

still reached genome-wide significance ($p = 3.95 \times 10^{-9}$) (Supplementary Table 5).

The association of previously reported variations with HCV-induced LC

Non-synonymous SNP rs738409 (I148M) in the *PNPLA3* gene was shown to be associated with progression of LC in the previous prospective study in Caucasians [31]. SNP rs738409 was also associated with the severity of non-alcoholic fatty liver disease in Japanese [48]. Therefore, we analyzed SNP rs738409 in our case-control cohort, but rs738409 did not significantly associate with HCV-induced LC ($p = 0.24$ and OR = 1.10), although the risk G allele was more frequent among LC than CHC (Supplementary Table 6). Our result is similar to what observed among Caucasians in the previous study, in which rs738409 increased liver cancer risk among alcoholic cirrhosis but did not among hepatitis C cirrhosis [49]. Since biological studies demonstrated that its risk allele (G) abolishes the triglyceride hydrolysis activity of *PNPLA3* [50] *PNPLA3* variation would have a strong impact on non-viral cirrhosis.

Recently, GWAS in the Caucasian population identified the association of SNPs rs4374383, rs16851720 and rs9380516 with the progression of liver fibrosis after HCV infection [51]. However, SNPs rs4374383 and rs16851720 did not exhibit significant association ($p = 0.654$ and 0.231 , respectively) in our sample set. Although SNP rs9380516 exhibited the association with p -value of 0.015, the risk allele showed an opposite result

Table 3. Results of three associated variations from candidate gene analyses.

Gene	Tagging SNP	Haplotype frequency		OR (95% CI) ^a		<i>p</i> value ^b
		Liver cirrhosis	Chronic hepatitis C			
DQA1*0601	rs2736182(T) + rs2071293(A)	0.038	0.019	2.80	1.38-3.32	4.53 × 10 ⁻⁴
DRB1*0405	rs411326(C) + rs2395185(A) + rs4599680(A)	0.324	0.266	1.45	1.15-1.56	1.54 × 10 ⁻⁴

Association was tested by comparing haplotype distribution between 682 liver cirrhosis and 1045 chronic hepatitis C samples in GWAS.

^a OR, odds ratio; CI, confidence interval.

^b *p* Values were obtained by case-control analysis of GWAS stage (*p* for haplotype were obtained by score test, implemented in R) (DQA1*0601 and DRB1*0405). The *p* values obtained by logistic regression analysis adjusted for age and gender under additive model.

(Supplementary Table 6). Taken together, these SNPs would not be associated with liver fibrosis in the Japanese population.

Genes related to extracellular matrix turnover or immune response (*KRT 19*, *COL1A1*, *STMN2*, *CXCL6*, *CCR2*, *TIMP1*, *IL8*, *IL1A*, *ITGA2*, *CLDN 4*, and *IL2*) were shown to be implicated in liver fibrosis of chronic hepatitis C [14]. To further characterize these loci, we conducted imputation analyses in the GWAS sample set (682 cases and 1045 controls), using data from HAPMAP phase II (JPT), and found 163 SNPs in 9 loci. However, none of these SNPs indicated significant association with *p*-value of less than 0.01 (Supplementary Table 7). Thus, variations of these genes did not associate with progression from chronic hepatitis C to liver cirrhosis.

Imputation-based fine mapping of HLA region

The most significantly associated SNP rs3135363 is located within an intergenic region between *BTNL2* and *HLA-DRA*, and rs910049 is located in intron 7 of *C6orf10* gene (Supplementary Figs. 5 and 6). To further characterize these loci, we conducted imputation-based association analysis for the GWAS samples (682 LC and 1045 CHC samples) using data from HAPMAP Phase II (JPT), and could obtain the results of nearly 6000 SNPs in a 4-Mb genomic region. The regional association plots revealed that all modestly-associated SNPs are confined within a 700-kb region containing 21 genes, namely *TNXB*, *ATF6B*, *FKBP1*, *PRRT1*, *PPT2*, *EGFL8*, *AGPAT1*, *RNF5*, *RNF5P1*, *AGER*, *PBX2*, *C6orf10*, *BTNL2*, *HLA-DRA*, *HLA-DRB5*, *HLA-DRB6*, *HLA-DRB1*, *HLA-DQA1*, *HLA-DQA2*, *HLA-DQB1* and *HLA-DQB2* (Supplementary Fig. 5). Although 640 SNPs, including ten non-synonymous SNPs within the 4-Mb region, showed very modest associations (*p* < 0.01) with HCV-induced LC, none of these SNPs in this region revealed strong association with HCV-induced LC, after adjustment with the two SNPs, rs910049 and rs3135363 (Supplementary Fig. 7). Taken together, the associations observed in this region would reflect the association with rs910049 and rs3135363.

Previous reports indicated the association of *HLA-DRB1* and *HLA-DQ* alleles with HCV-induced chronic hepatitis in the Japanese population [26]. To investigate the association of HLA alleles with HCV-induced LC, we estimated the genotypes at the HLA region by applying the imputation results of HLA-tagging SNPs [37]. We could successfully determine 53 alleles of *HLA-A*, *B*, *C*, *DQA*, *DQB*, and *DRB* genes and find that *HLA-DQA1*0601* and *HLA-DRB1*0405* were strongly associated with HCV-induced LC (*p* values of 4.53 × 10⁻⁴ and 1.54 × 10⁻⁴ with ORs of 2.80 and 1.45) even after the Bonferroni correction (*p* < 0.05/53 = 9.43 × 10⁻⁴) (Table 3 and Supplementary Table 8A-E) [37].




Fig. 2. Cumulative effects of liver cirrhosis risk alleles. (A) Frequency distribution divided by risk allele numbers (rs910049, rs3135353, and *HLA-DQA0601*) among liver cirrhosis (light blue bars) and chronic hepatitis C (dark blue bars) patients. (B) Plot of the increase odds ratio (OR) for liver cirrhosis according to the number of risk alleles. The ORs are relative to the subjects with no risk alleles (rs910049, rs3135353, and *HLA-DQA0601*). Vertical bars correspond to 95% confidence intervals. Horizontal line marks the null value (OR = 1).

Cumulative effect of multiple loci within the HLA region

SNPs rs3135363 and rs910049, *HLA-DQA1*0601*, and *HLA-DRB1*0405* are located within a 300-kb segment in the HLA class II region and show moderate linkage disequilibrium (Supplementary Fig. 8). To further evaluate these genetic factors, we performed multiple logistic regression analyses and found that rs910049 (*p* of 9.40 × 10⁻³ with OR of 1.38), rs3135363 (*p* of 3.94 × 10⁻⁴ with OR = 1.41), and *HLA-DQA1*0601* (*p* of 7.79 × 10⁻³ with OR of 1.54) were significantly associated with HCV-induced LC (Supplementary Table 9), indicating these three variations were independent risk factors for progression of CHC to LC.

To investigate the pathophysiological roles of rs910049 and rs3135363 in disease progression, we searched the eQTL database (<http://www.sph.umich.edu/csg/liang/imputation>) and found that risk alleles of rs910049 (A) and rs3135363 (T) were associated with lower expression of *HLA-DQA* (LOD of ≥ 6.86 and 17.31, respectively) and *DRB1* (LOD of ≥ 12.01 and 18.96, respectively), and with higher expression of *HLA-DQB1* (LOD of ≥ 6.76 and 4.46, respectively) (Supplementary Table 10). Thus, rs910049 and rs3135363 are likely to affect the expression of HLA class II molecules and subsequently alter the risk of HCV-induced LC.

Finally, we examined the cumulative effects of rs910049, rs3135363, and *HLA-DQA1*0601*. Individuals with four or more risk alleles (8.8% of general population) have 2.83-fold higher risk of HCV-induced LC compared with those with no risk allele (15.0% of general population, Fig. 2).